Samsung Biologics, a global contract development and manufacturing organization (CDMO), has extended its collaboration with LigaChem Biosciences, a biotech pioneering research and development of ADC candidates, to provide antibody-drug conjugate (ADC) services. Samsung Biologics will support a series of LigaChem Biosciences’ ADC programs at Samsung Biologics’ new dedicated ADC facility. The two companies have already been collaborating on ADC programs for the treatment of solid tu...